The incidence of invasive fungal infections is increasing in many hospitals. The National Nosocomial Infections Surveillance (NNIS) program for U.S. hospitals documented a doubling in the rate of nosocomial fungal infections between 1980 and 1990 (4) . From 1995 to 1996, Candida species was the fourth most common cause of nosocomial bloodstream infections (BSIs) in the United States (13) . In recent years, some studies have reported an increase of candidemia due to Candida non-albicans species, with the threat of increased mortality and antifungal drug resistance (1, 10, 16, 21) . The epidemiology of candidemia has been studied primarily in selected hospitals (2, 7, 22) ; few studies have focused on this problem on a nationwide basis (15, 17) . The purpose of this study was to examine candidemia in Iceland during a 20-year period with respect to epidemiology and clinical mycology. Due to the high quality and accessibility of demographic and medical data, Iceland, a 103,000-km 2 island in the north Atlantic ocean with 285,000 inhabitants, is well suited for epidemiological studies.
All patients in Iceland with yeast isolated from blood from 1 January 1980 to 31 December 1999 were identified retrospectively by a nationwide search in microbiology databases. During the first decade of the study, a Bactec (Becton Dickinson Microbiology Systems) radiometric system was most widely used. During the second decade of the study, the nonradiometric systems Bactec, Difco ESP (Becton Dickinson), and bioMérieux Vital (bioMérieux) were used. There are 2 university or university-affiliated hospitals and 14 county hospitals in the country. Three clinical microbiology laboratories process blood cultures from all of the hospitals. An episode of yeast BSI was defined as at least one blood culture positive for yeast. Episodes were considered separate if they occurred more than 2 weeks apart.
Viable yeast BSIs were subcultured on Sabouraud agar (Oxoid). Species identification was based on germ tube production, distinctive color, and morphology on CHROMagar (Hardy Diagnostics) and sugar assimilation profiles by using the API id32C system (bioMérieux). The MICs of amphotericin B, fluconazole, and itraconazole were determined by using an Etest (AB Biodisk) according to instructions from the manufacturer (Antifungal susceptibility testing of yeasts, Etest technical guide 4, AB Biodisk, Solna, Sweden, 1997). The plates were incubated at 35°C for 48 h before reading the MICs. The National Committee for Clinical Laboratory Standards (NCCLS) breakpoint criteria for antifungal susceptibility were used (9) .
National import figures on antifungal agents for the period from 1980 to 1999 were obtained from the Icelandic Association of Importers of Pharmaceuticals. The number of defined daily doses (DDD) per packing was calculated, and the import was expressed as DDD per 1,000 inhabitants per year. Information about national demographics, including age distribution, for the period from 1980 to 1999 was obtained from the Bureau of Statistics in Iceland. Information on admissions to pediatric, medical, and surgical wards at the university hospitals for each year of the study was obtained from annual hospital reports. The chi-square test for linear trend was used to compare incidence rates between study periods, and the chisquare test was used to compare fungal species distribution and proportions of blood cultures positive for yeasts between the first and second halves of the study period.
In the 20-year period from 1980 to 1999, 172 episodes of BSI with yeasts, predominantly candidemia, were diagnosed in 165 patients in Iceland. Children (Յ16 years) comprised 11 (7%) of the patients, and adults comprised 154 (93%) of the patients. Six patients had two or more separate episodes, occurring at least 2 weeks apart. The nationwide annual incidence of candidemia and number of candidemic episodes per 1,000 admissions to the university hospitals is shown in Fig. 1 . A vast majority of the patients (87%) came from the university hospitals. Figure 2 shows the age-specific incidence for the first and second halves of the observation period, respectively. During the second decade of the study, the use of blood cultures at the two university hospitals increased from 71,002 vials between 1990 and 1994 to 93,032 between 1995 and 1999. The proportion of blood cultures positive for yeasts increased slightly, from 0.187% between 1990 and 1994 to 0.204% be-tween 1995 and 1999, but this increase was not significant (P ϭ 0.464). Table 1 shows the yeast species that were cultured from the blood of Icelandic patients from 1980 to 1999. Species distribution remained relatively stable in the country, with C. albicans causing around two-thirds of infections (range, 63.4 to 65.3%) and Candida non-albicans species causing one-third. There was no significant change in yeast species distribution between the first and second halves of the study (P ϭ 0.35). Species identification of all available isolates revealed Candida dubliniensis in four cases.
The MICs of amphotericin B, fluconazole, and itraconazole were determined for 99 strains dating from 1991 to 1999 (Table  2 ). All were susceptible to amphotericin B (MIC, Յ1 g/ml), 97% were susceptible to fluconazole (MIC, Յ8 g/ml), and 87% were susceptible to itraconazole (MIC, Յ0.125 g/ml). During the study period, the number of isolates classified as susceptible-dose dependent for itraconazole increased from 6.7% (3 of 45) between 1991 and 1995 to 16.7% (9 of 54) between 1996 and 1999, but this increase was not statistically significant.
The national import of antifungal agents from 1990 to 1999 is shown in Table 3 . Fluconazole was approved for oral and parenteral use in 1990. During the period from 1991 to 1999, the import of oral formulations increased from 9.4 to 47.6 DDD/1,000 inhabitants/year (406%) and the import of fluconazole for parenteral use increased from 0.5 to 1.8 DDD/1,000 inhabitants/year (260%).
Several studies have shown a substantial increase in the incidence of candidemia in the past 2 decades. Data from the NNIS system on nosocomial BSIs showed an up to fivefold increase in incidence between 1980 and 1989 in the United States (3). According to another surveillance study from the NNIS program, between 1995 and 1996 Candida species was the fourth most common cause of nosocomial BSI (13) . Our data show that the incidence of candidemia in Iceland has increased steadily and significantly over the past 2 decades. The incidence is somewhat higher than that documented in a nationwide study in Norway from 1991 to 1996 (an average of 0.17 per 1,000 discharges) (17) but similar to that observed in Israel in 1994 (0.50 per 1,000 admissions) (15) . Although the use of blood cultures increased at the university hospitals, the proportion of cultures that turned out positive for yeasts remained stable. The observed increase may be due in part to improved detection, but other factors are likely to have played a role. Among them are the greater use of invasive devices and broad-spectrum antibacterial agents, more extensive surgical procedures, and advanced life support (5, 18) . The length of stay at the university hospitals in Iceland, where 87% of the patients were diagnosed, did not increase in the past 2 decades and therefore does not explain our findings.
Many studies on the epidemiology of fungal BSIs have focused on selected hospitals or hospital wards, with different patient populations, and have reported a substantially higher incidence than is reported in this study. According to two studies on candidemia, one in Australia and one in the United States, the incidence was 1.5 and 3.3 episodes per 1,000 discharges, respectively (7, 19) . Another study at the M.D. Anderson Cancer Center reported an incidence of 6 cases of fungemia per 1,000 admissions between 1988 and 1992 (2). A prospective multicenter study of candidemia at six sites in the United States concluded that the incidence was 9.8 cases/1,000 admissions in surgical intensive care units (ICUs) and 12.3 cases/1,000 admissions in neonatal ICUs (14) .
Studies on candidemia and pathogen species distribution from different parts of the world generally agree that C. albicans is still the most commonly isolated fungal pathogen from blood, causing between 50 and 70% of infections (12, 14, 22) . According to our data, approximately two-thirds (64.4%) of fungal BSIs in Iceland were caused by C. albicans and onethird were caused by Candida non-albicans species. These results are comparable to those reported from Norway (17) but somewhat higher than those reported from the United States, Canada, Latin America, and Europe (11) . Among the different fungal species, we identified C. dubliniensis as the pathogen in four cases. This species, which was originally described by Sullivan and coworkers in 1995 (20) , is germ tube positive and can therefore easily be mistaken for C. albicans (6) . The proportion of candidemias caused by Candida non-albicans has not increased in the past 20 years according to our results. In contrast, other studies have reported a shift towards Candida non-albicans species in the past 5 to 10 years (2, 16). Antifungal prophylaxis with fluconazole may have played a role in this observed shift. In two studies, fluconazole prophylaxis was the FIG. 2. Age-specific incidence of fungal BSIs in Iceland from 1980 to 1999 calculated for the first and second decades of the study. As shown, the age-specific incidence was similarly distributed in the first (open circles, solid lines) and the second (filled circles, dashed lines) decades, with the exception of the youngest age group (Ͻ1 year old). The incidence was low in people aged 5 to 40 years but started to rise among people aged 41 to 50 years. Incidence subsequently increased with advancing age, peaking among patients aged 61 to 70 years (1980 to 1989, 12.7 cases/100,000 inhabitants/year; 1990 to 1999, 19.3 cases/100,000 inhabitants/year). From 1980 to 1989, no children of Ͻ1 year of age were diagnosed with candidemia. After 1989, however, the incidence followed a biphasic pattern, with a high incidence occurring in the youngest age group (Ͻ1 year, 11.3 cases/100,000 inhabitants/year). Most of the children younger than 1 year old were preterm infants in the neonatal ICU at the time of diagnosis. single most important determinant for the relative increase in Candida krusei and Candida glabrata infections (2, 8) . Fluconazole prophylaxis is used infrequently in Iceland, which may explain this difference. The antifungal susceptibility patterns revealed that 97% of the Icelandic strains were susceptible to fluconazole, despite an approximately fourfold increase in fluconazole import in the past decade. Little has been published about national consumption of antifungal agents. Our results can be compared to data from the study conducted in Norway, where the use of fluconazole increased from 8.0 to 16.1 DDD/1,000 inhabitants/ year between 1991 and 1996 (17) . During the same period, a greater increase in fluconazole import was seen in Iceland: from 9.9 to 24.9 DDD/1,000 inhabitants/year. The use of amphotericin B remained relatively stable.
In conclusion, this study has shown that, on a national level, the incidence of candidemia in Iceland has increased 3.5-fold over the past 2 decades, with the highest incidences of infection occurring in the youngest and older age groups. The proportion of infections caused by Candida non-albicans species has remained stable. Fluconazole use has increased approximately fourfold in the past decade, but the majority of strains are still susceptible to this agent. b DDD were as follows: amphotericin B (AmB), 35 mg; fluconazole (FLU), itraconazole (ITZ), and ketoconazole (Keto), 200 mg each; 5-flucytosine (5-FC), 10 g; terbinafine (Terb), 250 mg; nystatin, 1,500,000 IUs; griseofulvin (Griseo), 500 mg.
